Table 1.
Comparison of the baseline features and IHC results between CD5+ and CD5- DLBCL.
| Characteristics | CD5+ DLBCL (N = 24) | CD5- DLBCL (N = 23) | P value |
|---|---|---|---|
| n (%) | n (%) | ||
| Baseline features | |||
| Median age (years) | 66 (43–85) | 64 (29–82) | 0.237 |
| Age >60 (years) | 15 (62.5) | 13 (56.5) | 0.676 |
| Sex: Men | 13 (54.2) | 12 (52.2) | 0.891 |
| Extranodal sites (≥2) | 3 (12.5) | 4 (17.4) | 0.638 |
| ECOG PS (2–4) | 2 (8.3) | 4 (17.4) | 0.297 |
| Elevated LDH | 12 (50.0) | 7 (30.4) | 0.172 |
| Stage III/IV | 14 (58.3) | 12 (52.2) | 0.671 |
| IPI (>3) | 8 (33.3) | 7 (30.4) | 0.831 |
| NCCN-IPI (4–8) | 8 (33.3) | 8 (34.7) | 0.917 |
| BM involvement | 1 (4.2) | 0 (0) | 0.322 |
| CNS involvement | 0 (0) | 1 (4.3) | 0.302 |
| B symptoms | 3 (12.5) | 1 (4.3) | 0.317 |
| Bulky tumor | 0 (0) | 0 (0) | 0.527 |
| Hypoalbuminemia | 3 (12.5) | 0 (0) | 0.080 |
| HBV infection | 1 (4.2) | 13 (56.5) | 0.276 |
| Morphological features | |||
| Centroblastic variant | 21 (87.5) | 21 (91.3) | >0.999 |
| Immunoblastic variant | 3 (12.5) | 1 (4.3) | 0.609 |
| Anaplastic variant | 0 (0) | 1 (4.3) | 0.489 |
| IHC features | |||
| MYC+ | 17 (70.8) | 2 (8.7) | <0.001 |
| BCL2+ | 14 (58.3) | 11 (47.8) | 0.471 |
| BCL6+ | 14 (58.3) | 19 (82.6) | 0.069 |
| MYC+/BCL2+ | 9 (37.5) | 0 (0) | 0.001 |
| MYC+/BCL6+ | 10 (41.6) | 1 (4.3) | 0.003 |
| MYC+/BCL2+/BCL6+ | 5 (20.8) | 6 (26.1) | 0.671 |
| P53+ | 4 (16.6) | 3 (13.0) | 0.727 |
| CD10+ | 9 (37.5) | 8 (34.8) | 0.846 |
| MUM1+ | 10 (41.7) | 10 (43.5) | 0.900 |
ECGO PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; IPI, International Prognostic Index; NCCN, National Comprehensive Cancer Network; BM, bone marrow; CNS, central nervous system; HBV, hepatitis B virus; IHC, immunohistochemistry. The P values that <0.05 were presented in bold font.